Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation | Zendy

Carl van Walraven | Zendy; Robert G. Hart | Zendy; Stuart J. Connolly | Zendy; Peter C. Austin | Zendy; Jonathan Mant | Zendy; Richard Hobbs | Zendy; Peter J. Koudstaal | Zendy; Palle Petersen | Zendy; Francisco Pérez-Gómez | Zendy; J. André Knottnerus | Zendy; B. S. P. Boode | Zendy; Michael D. Ezekowitz | Zendy; Daniel E. Singer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation

Author(s) -

Carl van Walraven,

Robert G. Hart,

Stuart J. Connolly,

Peter C. Austin,

Jonathan Mant,

Richard Hobbs,

Peter J. Koudstaal,

Palle Petersen,

Francisco Pérez-Gómez,

J. André Knottnerus,

B. S. P. Boode,

Michael D. Ezekowitz,

Daniel E. Singer

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.108.526988

Subject(s) - medicine , atrial fibrillation , stroke (engine) , cardiology , ischemic stroke , ischemia , mechanical engineering , engineering

Stroke risk increases with age in patients who have nonvalvular atrial fibrillation. It is uncertain whether the efficacy of stroke prevention therapies in atrial fibrillation changes as patients age. The objective of this study was to determine the effect of age on the relative efficacy of oral anticoagulants (OAC) and antiplatelet (AP) therapy (including acetylsalicylic acid and triflusal) on ischemic stroke, serious bleeding, and vascular events in patients with atrial fibrillation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research